UNSPSC 51162100: Combination antituberculars

This classification denotes combination drugs used in the treatment of tuberculosis, any of the infectious diseases of man and other animals caused by species of mycobacterium. such drugs are divided into two main classes: first-line agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and second-line drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.

Typical combination antitubercular constituents are isoniazid, pyrazinamide, pyridoxine, and rifampin.

UNSPSC 51162100 Combination antituberculars is a Class code, but the recent state and local opportunities tagged under it show a significant mismatch with the code's nominal scope. The records include naloxone and drug deactivation systems for a Florida county health initiative, on-site pharmacy services for a Georgia county employer health plan, generic pharmaceuticals and OTC products through a multistate cooperative purchasing alliance, and an exploratory RFI from Texas HHS regarding direct-to-manufacturer prescription programs—none of which involve combination antitubercular medications. The only opportunity directly aligned with the code's stated scope is a Utah Department of Health and Human Services sole-source amendment to fund tuberculosis housing services for homeless individuals, which provides accommodation and living support rather than pharmaceutical procurement. The code shows little relevant recent activity in actual combination antitubercular acquisition.

The issuing bodies span state health departments (Utah, Texas), county governments (Seminole County Florida, Hall County Georgia), and multistate cooperative purchasing vehicles (MMCAP administered by Minnesota). Geographic activity appears concentrated in the South and Upper Midwest, though the MMCAP opportunity extends nationally across participating jurisdictions including Oregon. The mismatch between the code classification and the actual work being solicited—naloxone, general pharmacy services, and OTC products rather than antitubercular combinations—suggests either tagging inconsistency in the source data or substantial drift between the code's intended scope and how state and local procurement offices are currently using it. Firms evaluating this code should verify whether opportunities are genuinely sourcing combination antituberculars or whether the classification is misleading for their specific product and service line.